We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Patrick
Kierkegaard
p.kierkegaard@imperial.ac.uk
Patrick
Kierkegaard
p.kierkegaard@imperial.ac.uk
Patrick
Kierkegaard
p.kierkegaard@imperial.ac.uk
Malignant neoplasms of digestive organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
What are the aims of the study?
To develop a toolkit that will help assess general practices readiness to adopt specific types of novel pancreatic cancer biomarker tests and provide recommendations for optimisation.
Why is this so relevant and important for people affected by pancreatic cancer?
Getting these tests into primary care will be difficult because many general practices may not be ready or able to use them. Patients living in deprived or rural areas may not have access to the tests. Surgeries may not have the trained staff or money available to use the tests. Our “toolkit” will find out if different types of general practices are able and ready to start using these new tests and identify what support they will need from the NHS to be prepared.
Why is this project innovative in the field of pancreatic cancer?
There is no procedure in place that can specifically check and measure how ready general practices are to adopt new pancreatic cancer tests and identify what support and resources are needed to facilitate adoption.
What are you planning to do?
We will talk to healthcare professionals, patients, carers, and key decision makers to find out what support and advice is needed so that doctors’ surgeries can prepare and plan to use the new tests.
We will hold focus groups with patients, carers, healthcare professionals, and key decision makers will discuss the results from the first part of the study and co-design the toolkit. We will make sure that our toolkit will have a real impact in primary care.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Qualitative;
You can take part if:
You may not be able to take part if:
GPs • Individuals who are unwilling to take part in the study. • Individuals with no experience in adopting new tests and guidelines into practice. • Individuals with no experience in in detecting, managing, and referring patients with symptoms of pancreatic cancer and/or are at an increased risk of developing pancreatic cancer. • Individuals who do not adequately understand verbal explanations or written information in English. Practice Staff • Individuals who are unwilling to take part in the study. • Individuals who are not familiar with adopting new tests and guidelines into practice. • Individuals who do not adequately understand verbal explanations or written information in English. PCN/GP FEDERATION/ICS REPRESENTATIVES • Individuals who are unwilling to take part in the study. • Individuals with no experience in developing and launching local and regional initiatives to support the adoption on new interventions across primary care practices. • Individuals who do not adequately understand verbal explanations or written information in English. Patients • Individuals who are unwilling to take part in the study. • Individuals who do not adequately understand verbal explanations or written information in English. • Unable to provide written and verbal consent.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Patrick
Kierkegaard
p.kierkegaard@imperial.ac.uk
Patrick
Kierkegaard
p.kierkegaard@imperial.ac.uk
Patrick
Kierkegaard
p.kierkegaard@imperial.ac.uk
The study is sponsored by Imperial College of Science, Technology and Medicine and funded by PANCREATIC CANCER UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 61961
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
